GlassScriptPhysician profile
Rachael E Lamkin Weaver
NPI 1982931507
$3,660.88
in general payments reported to CMS, 2019-2025
35 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $972 · 2023: $1,010 · 2024: $679 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.70 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,523.09 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $504.67 | 2021-2025 | |
| Novo Nordisk INC | $204.35 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $192.05 | 2022-2024 | Emgality, Reyvow |
| E.R. Squibb & Sons, L.L.C. | $124.63 | 2021 | |
| Lundbeck LLC | $104.45 | 2022-2025 | Vyepti, Rexulti |
| Livanova USA, INC. | $98.17 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $80.99 | 2022-2023 | Mavenclad |
| Amneal Pharmaceuticals LLC | $76.90 | 2022-2024 | Rytary |
| Ucb, INC. | $65.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.55 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $54.52 | 2022-2023 | Ongentys, Ingrezza |
| Cala Health, INC. | $45.58 | 2025 | Cala Kiq |
| Biogen, INC. | $44.24 | 2022-2023 | Tysabri |
| Celgene Corporation | $42.50 | 2022-2023 | Zeposia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $42.31 | 2022-2023 | |
| Harmony Biosciences LLC | $33.45 | 2022 | |
| Eisai INC. | $33.33 | 2022 | |
| Ge Healthcare | $28.83 | 2022-2023 | |
| Genentech USA, INC. | $28.25 | 2024 | Enspryng, Ocrevus |
| Alexion Pharmaceuticals, INC. | $25.31 | 2021-2023 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $24.01 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.49 | 2023 | Keveyis |
| Kyowa Kirin, INC. | $21.09 | 2021 | |
| Argenx US, INC. | $19.45 | 2023 | Vyvgart |
| Collegium Pharmaceutical, INC. | $18.60 | 2022 | |
| Sk Life Science, INC. | $17.79 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.40 | 2022 | |
| Amgen INC. | $15.82 | 2022 | |
| Tg Therapeutics, INC. | $15.68 | 2023 | |
| Pfizer INC. | $15.61 | 2024 | |
| Genzyme Corporation | $14.77 | 2022 | |
| Acadia Pharmaceuticals INC | $14.20 | 2023 | Nuplazid |
| Neurelis, INC. | $13.64 | 2023 | Valtoco |
| Nevro Corp. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Lamkin Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.